Tangram Therapeutics Advances TGM-312 Into MASH Patient Cohorts
London, UK, September 3, 2026 Tangram Therapeutics announced that its investigational MASH treatment TGM-312 has progressed into Part B...
Liver Disease
Advertisement
Inventiva Completes Phase 3 NATiV3 Trial of Lanifibranor in MASH
Daix, France and New York, September 2, 2026 Inventiva announced that the last patient has completed the final 72-week...
Resolution Therapeutics Expands U.S. Access for RTX001
EDINBURGH, UK & LONDON, UK, Sept. 1, 2026 Resolution Therapeutics Limited has partnered with Blood Centers of America, Inc....
GSK Wins Japan Approval for Hibsago in Hepatitis B
LONDON, UK, Aug 24, 2026 GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
Rectify Advances RTY-406 as Potential Disease-Modifying Therapy for PSC
Boston, Mass. – August 27, 2026 Rectify Pharmaceuticals presented the discovery and characterization of RTY-406, an oral, once-daily investigational...
Advertisements
Aligos Therapeutics Starts Phase 1 Study of ALG-170675
SOUTH SAN FRANCISCO, Calif., August 12, 2026 Aligos Therapeutics, Inc. announced that its partner Xiamen Amoytop Biotech Co., Ltd....
Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder
GAITHERSBURG, Md., July 28, 2026 Altimmune, Inc. announced positive topline results from its Phase 2 RECLAIM clinical trial evaluating...
Atea Pharmaceuticals Achieves Phase 3 Success in Hepatitis C Trial
BOSTON, July 28, 2026 Atea Pharmaceuticals announced positive topline results from its pivotal Phase 3 C-BEYOND trial, with its...
Roche Releases First Fully Automated HDV Test
BASEL, Switzerland, July 14, 2026 Roche has introduced the cobas® Hepatitis D Virus (HDV) test, the first fully automated,...
Madrigal Pharmaceuticals Secures Three New Resmetirom U.S. Patents
CONSHOHOCKEN, Pa., July 13, 2026 Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued three...
Advertisement
